New Jersey is currently home to 1696 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610
Recruiting
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). P... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/12/2025
Locations: Local Institution - 2110, New Brunswick, New Jersey
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Register for Updates
Quantifying Uterine Elastography in Menstruating Women
NCT06816381
Recruiting
This study is aiming to characterize the elasticity of the female reproductive tract including the uterus, cervix and ovary using shear wave elastography at different times during the menstrual cycle and define the standard reference range of normal uterine and ovarian elasticity. By doing so, the potential of using shear wave elastography to diagnose and predict outcomes for patients seeking fertility treatment might be established.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
02/11/2025
Locations: RMA, Basking Ridge, New Jersey
Conditions: Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Register for Updates
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT06699056
Recruiting
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily act... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Register for Updates
Speech and Arm Combined Exergame
NCT06817941
Recruiting
The purpose of this study is to develop innovative home therapy games to train the weak arm and improve speech intelligibility (clarity) of children with hemiplegia from cerebral palsy. The investigators are exploring the effects of these therapy games and how they change the children's speech, hand movement, and brain activation. 15 children who are 8-17 years old will be recruited for this study. These children should have a diagnosis of cerebral palsy, mild to moderate speech issues but use... Read More
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
02/07/2025
Locations: Rutgers School of Health Professions, Newark, New Jersey
Conditions: Cerebral Palsy (CP), Dysarthria
Register for Updates
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
NCT05323253
Recruiting
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as well as to assess the Duration of Response (DOR) 6 months from initial response. Secondary objectives are to assess the safety of DaRT, and to assess the progression free survival (PFS), overall survival... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Schweiger Dermatology Group, Hackensack, New Jersey
Conditions: Recurrent Squamous Cell Carcinoma
Register for Updates
Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling As Effective As Antibiotic Prophylaxis?
NCT06810687
Recruiting
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to a... Read More
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
02/05/2025
Locations: Atlantic Health, Morristown, New Jersey
Conditions: Urinary Tract Infection (Diagnosis)
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Jersey Shore University Medical Center, Neptune, New Jersey
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
NCT03396341
Recruiting
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
02/05/2025
Locations: Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey
Conditions: Genetic Testing, BRCA1/2
Register for Updates
Validating Incubators in the Lab: Optimizing Culture and Investigating BlasTulation Yield
NCT06214936
Recruiting
The goal of this study is to determine if benchtop incubators improve the number of embryos making it to the blastocyst stage of development (about 4-6 days after fertilization) in people undergoing in vitro fertilization (IVF) treatment for their infertility. * Test the effectiveness of the benchtop incubator. * Determine if the number of embryos reaching the blastocyst stage of embryo development (the stage that the embryos are biopsied for PGT-A and frozen) is improved in the benchtop incuba... Read More
Gender:
FEMALE
Ages:
Between 18 years and 41 years
Trial Updated:
02/04/2025
Locations: Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey
Conditions: Infertility
Register for Updates
Platelet Rich Plasma for Insufficient Endometrium
NCT05538338
Recruiting
To determine the effectiveness of an intrauterine PRP infusion on endometrial thickness and in vitro fertilization (IVF) outcomes in a population of infertile women with a history of unresponsive thin endometrium.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
02/04/2025
Locations: Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey
Conditions: Infertility of Uterine Origin
Register for Updates
Discarded Materials Study
NCT01219335
Recruiting
Use of discarded embryos to advance laboratory expertise and technology in the area of human embryo development and assisted reproductive technologies
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2025
Locations: Reproductive Medicine Associates of new Jersey, Basking Ridge, New Jersey
Conditions: Infertility
Register for Updates
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
NCT05714072
Recruiting
The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Myelofibrosis Due to and Following Polycythemia Vera
Register for Updates